Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Ralph SmallingHead of Regulatory | GeneluxGNLX | Open-market sale | 06/03 | 06/04 | 192 sh | $2.93 | $562.56 | −0.3% |
John ThomasDirector | GeneluxGNLX | Open-market sale10b5-1 plan | 06/01 | 06/02 | 10,000 sh | $2.98 | $29,800 | −2.1% |
Yong YuChief Scientific Officer | GeneluxGNLX | Open-market sale | 05/11 | 05/12 | 605 sh | $2.97 | $1,796.85 | −0.4% |
Thomas ZindrickPresident and CEO | GeneluxGNLX | Open-market sale | 05/11 | 05/12 | 2,798 sh | $2.94 | $8,226.12 | −0.5% |
Joseph CappelloChief Technical Officer | GeneluxGNLX | Open-market sale | 05/11 | 05/12 | 605 sh | $2.97 | $1,796.85 | −0.4% |
Ralph SmallingHead of Regulatory | GeneluxGNLX | Open-market sale | 05/11 | 05/12 | 270 sh | $2.98 | $804.6 | −0.4% |
GeneluxGNLX | Open-market sale | 03/24–03/25 | 03/26 | 585 sh2 trades | $2.46avg. | $1,437.3 | −0.9% | |
Yong YuSVP, Clinical Development | GeneluxGNLX | Open-market sale | 03/24 | 03/26 | 906 sh | $2.42 | $2,192.52 | −0.6% |
Thomas ZindrickPresident and CEO | GeneluxGNLX | Open-market sale | 03/24 | 03/26 | 3,582 sh | $2.42 | $8,668.44 | −0.7% |
Joseph CappelloChief Technical Officer | GeneluxGNLX | Open-market sale | 03/24 | 03/26 | 906 sh | $2.42 | $2,192.52 | −0.6% |
John ThomasDirector | GeneluxGNLX | Open-market sale10b5-1 plan | 03/02 | 03/03 | 10,000 sh | $2.90 | $29,000 | −2.0% |
GeneluxGNLX | Open-market sale | 25/08/21–25/11/17 | 25/12/11 | 4,192 sh2 trades | $3.83avg. | $16,040.85 | −2.8% | |
GeneluxGNLX | Open-market sale | 25/08/21–25/11/17 | 25/12/11 | 17,182 sh2 trades | $3.87avg. | $66,414.42 | −3.1% | |
GeneluxGNLX | Open-market sale | 25/08/21–25/11/17 | 25/12/11 | 3,706 sh3 trades | $3.88avg. | $14,369.79 | −2.3% | |
GeneluxGNLX | Open-market sale | 25/08/21–25/12/05 | 25/12/09 | 2,332 sh4 trades | $3.75avg. | $8,744.4 | −3.3% | |
John ThomasDirector | GeneluxGNLX | Open-market sale10b5-1 plan | 25/12/01 | 25/12/02 | 10,000 sh | $5.00 | $50,000 | −2.0% |
Yong YuVP, Clinical Trial Operations | GeneluxGNLX | Open-market sale | 25/05/12 | 25/05/13 | 5,579 sh | $2.92 | $16,290.68 | −10.5% |
Sean RyderGeneral Counsel | GeneluxGNLX | Open-market sale | 25/05/12 | 25/05/13 | 4,475 sh | $2.92 | $13,067 | −8.6% |
Thomas ZindrickPresident and CEO | GeneluxGNLX | Open-market sale | 25/05/12 | 25/05/13 | 10,764 sh | $2.92 | $31,430.88 | −5.3% |
Joseph CappelloVP, Pharmaceutical Development | GeneluxGNLX | Open-market sale | 25/05/12 | 25/05/13 | 4,737 sh | $2.92 | $13,832.04 | −8.3% |